Misplaced Pages

Siplizumab: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 08:13, 9 December 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacol...← Previous edit Revision as of 21:35, 19 November 2015 edit undoDePiep (talk | contribs)Extended confirmed users294,285 editsm Identifier not assigned: use =none (CAS RN, ChemSpider, ATC) (via AWB script)Next edit →
Line 2: Line 2:
| Verifiedfields = changed | Verifiedfields = changed
| verifiedrevid = 464392011 | verifiedrevid = 464392011
<!-- Monoclonal antibody data -->

<!--Monoclonal antibody data-->
| type = mab | type = mab
| mab_type = mab | mab_type = mab
| source = zu/a | source = zu/a
| target = ] | target = ]
<!-- Clinical data -->

<!--Clinical data-->
| tradename = | tradename =
| pregnancy_AU = | pregnancy_AU =
Line 20: Line 18:
| legal_status = | legal_status =
| routes_of_administration = | routes_of_administration =
<!-- Pharmacokinetic data -->

<!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
| protein_bound = | protein_bound =
Line 27: Line 24:
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =
<!-- Identifiers -->

<!--Identifiers-->
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = NA | ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}} | CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 288392-69-8 | CAS_number = 288392-69-8
Line 40: Line 36:
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05847 | KEGG = D05847
<!-- Chemical data -->

<!--Chemical data-->
| chemical_formula = | chemical_formula =
| molecular_weight = | molecular_weight =

Revision as of 21:35, 19 November 2015

Pharmaceutical compound
Siplizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from rat)
TargetCD2
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
  (what is this?)  (verify)

Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.

References

  1. ClinicalTrials.gov
Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)
Antimetabolites
Macrolides/
other IL-2 inhibitors
IMiDs
Intracellular
(reception)
IL-1 receptor antagonists
mTOR
Extracellular
Antibodies
Monoclonal
Serum target
(noncellular)
Cellular
target
Unsorted
Polyclonal
-cept (Fusion)
Unsorted
Monoclonal antibodies for the immune system
Immune system
Human
Mouse
Chimeric
Humanized

Immune activation: Dostarlimab
Other: Ibalizumab

Chimeric + humanized
Interleukin
Human
Humanized
Veterinary
Inflammatory lesions
Mouse


Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Siplizumab: Difference between revisions Add topic